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■ LETTER TO THE EDITOR ■
We appreciate the interest of Dr Yin on the issue of
tamoxifen and breast cancer [1] that we recently pre-
sented [2]. This intersection of the widely used tamoxifen
and a relatively common cancer of women presents a
vexing clinical scenario: How should positive estrogen
receptor (ER) breast cancer be managed? Dr Yin intro-
duces another variable into the question with our com-
ment about reconsideration of tamoxifen use for breast
cancer [2]. We are happy to provide further evidence
to address this. We never overlooked the possible un-
wanted events of raloxifene use. We do not know why
the author should emphasize this, because the author
wrote that “the use of raloxifene is not without side
effects” [1]. In addition, the author cited the article by
Premkumar and colleagues to show the occurrence of
ovarian simulation and endometrial polyps in premeno-
pausal women who were treated with raloxifene [3].
Furthermore, the author cited the RUTH  (Raloxifene
Use for The Heart) trial data to show that there was a
small increase in stroke mortality [4]. If the author had
considered the effects of other selective estrogen recep-
tor modulators (SERMs) including clomiphene and
tamoxifen, these findings would not be so surprising.
In fact, the link between sex hormones and breast
cancer growth and development has been recognized for
more than a century [5]. Both endogenous and exoge-
nous sex hormones have been implicated in the patho-
genesis of breast cancer. Estrogen is mediated through
related but distinct ERs, designated ERα and ERβ, to
alter gene expression [6–9]. An accumulated understand-
ing of the mechanism of action of estrogen ultimately
led to the design of antiestrogenic agents that work 
by virtue of their interaction with the ER; these drugs
have come to be known as SERMs [10]. Tamoxifen, a
SERM, emerged as the first antiestrogenic agent that
was clinically applicable to breast cancer [2].
We completely agree with Dr Yin’s view that the use
of tamoxifen to prevent breast cancer and decrease
recurrence is not controversial [1]. In fact, in the review
of the role of SERMs in breast cancer, we directly pointed
out the important value of tamoxifen in treating breast
cancer [10]. We wrote that tamoxifen has become the
“gold standard”, and established the principles of tumor
targeting and identified the appropriate treatment
strategy to aid survival in breast cancer patients, with
enhancement of disease-free survival, and a 50% decrease
in recurrence observed in ER-positive patients 15 years
after diagnosis [10].
However, due to the many adverse events with the
use of tamoxifen, some of which have contributed to
significant morbidity and mortality [2], drug modifi-
cation, which yields a lower incidence of adverse events
without compromising the therapeutic effect for breast
cancer prevention, may face an easier road to acceptance.
Raloxifene may be a better alternative, since evidence
from large clinical trials has shown that raloxifene not
only decreases the incidence of osteoporosis and related
fractures, but also offers benefits in breast cancer pre-
vention. The results of the Study of Tamoxifen and
Raloxifene (STAR) trial showed the superiority of ralox-
ifene over tamoxifen, not only in its equal efficacy in the
prevention of invasive breast cancer but also in having
fewer serious adverse events [11]. Some important data
from STAR include the similar incidence of invasive breast
cancer in both groups (163 cases in the tamoxifen group
and 168 in the raloxifene group: 4.30 per 1,000 vs. 4.41
per 1,000; relative risk, RR, 1.02; 95% confidence interval,
CI, 0.82–1.28); and a lower incidence of thromboem-
bolic events (141 cases in the tamoxifen group and 100
in the raloxifene group: 3.71 per 1,000 vs. 2.61 per 1,000;
RR, 0.70; 95% CI, 0.54–0.91); fewer cataracts (394
cases in the tamoxifen group and 313 in the raloxifene
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group: 12.30 per 1,000 vs. 9.72 per 1,000; RR, 0.79; 95%
CI, 0.68–0.92), fewer cataract surgeries (260 cases in
the tamoxifen group and 215 in the raloxifene group:
8.03 per 1,000 vs. 6.62 per 1,000; RR, 0.82; 95% CI,
0.68–0.99); fewer endometrial hyperplasia events with
atypia or without atypia (84 cases in the tamoxifen
group and 14 in the raloxifene group: 4.69 per 1,000
vs. 0.76 per 1,000; RR, 0.16; 95% CI, 0.09–0.29), and
fewer hysterectomies (244 cases in the tamoxifen group
and 111 in the raloxifene group: 13.57 per 1,000 vs.
6.04 per 1,000; RR, 0.44; 95% CI, 0.35–0.56) in the
women taking raloxifene. Although they did not achieve
statistical significance, the data are interesting, nonethe-
less. There were fewer cases of noninvasive breast cancer
in the tamoxifen group (57 cases) than in the raloxifene
group (80 cases) (1.51 vs. 2.11 per 1,000; RR, 1.40; 95%
CI, 0.98–2.00), but there were more cases of uterine
cancer in the tamoxifen group (36 cases) than in the
raloxifene group (23 cases) (2.00 vs. 1.25 per 1,000; RR,
0.62; 95% CI, 0.35–1.08). In addition, there were no
significant differences between tamoxifen and raloxifene
in patient-reported outcomes for physical and mental
health or depressive symptoms, and scores on all of these
measures were well within the normal ranges for healthy
women of this age [11], although women in the tamox-
ifen group reported having better sexual functioning
(age-adjusted repeated measure odds ratio, 1.22%; 95%
CI, 1.01–1.46), and less mean symptom severity of
musculoskeletal problems (1.15 vs. 1.10; p = 0.002),
dyspareunia (0.78 vs. 0.68; p < 0.001), and weight gain
(0.82 vs. 0.76; p < 0.001). However, women in the ralox-
ifene group reported benefits in relation to gynecologic
problems, vasomotor symptoms, leg cramps and bladder
control, and women in the tamoxifen group had greater
mean symptom severity for gynecologic problems (0.29
vs. 0.19; p < 0.001), vasomotor symptoms (0.96 vs. 0.85,
p < 0.001), leg cramps (1.10 vs. 0.91; p < 0.001), and
bladder control symptoms (0.88 vs. 0.73; p < 0.001)
[12]. In terms of side effects, raloxifene is superior to
tamoxifen. Of course, we never suggested that raloxifene
could replace tamoxifen in patients who had breast
cancer. Before reaching the above conclusion, thera-
peutic efficacy should be evaluated. Unfortunately, no
answer is available for this yet.
Finally, other new adjuvant hormone therapies for
breast cancer, such as aromatase inhibitors (AIs) or even
ER antagonists, have been available for the manage-
ment of breast cancer. For example, a recent publica-
tion (Arimidex, Tamoxifen, Alone or in Combination
trial: ATAC trial) [13] demonstrated the superiority of
anastrozole to tamoxifen, by showing its long-term
safety outcomes and establishing clearly its long-term
efficacy compared with tamoxifen, as an initial adjuvant
treatment for postmenopausal women with hormone-
sensitive and early breast cancer, and providing statis-
tically significant evidence of it having a longer carryover
effect after 5 years of adjuvant treatment [13]. However,
regarding the same issue, the editorial comment was that
we still need to pay attention to the long-term follow-up
findings, not only of this trial but also of other trials
containing AIs, because an advantage in terms of overall
survival has not yet been confirmed [14]. In addition,
the toxicities of the AIs are generally acceptable, with
fewer endometrial cancers, gynecologic complaints
and thromboembolic events, but there are more bone
fractures and arthralgias compared with tamoxifen
alone [15].
In summary, with no other competition, tamoxifen
became the “gold standard” and established the princi-
ples of tumor targeting and identifying an appropriate
treatment strategy to aid survival in breast cancer patients
[16]. Adjuvant 5-year tamoxifen enhanced disease-free
survival, and there was a 50% decrease in recurrence
observed in ER-positive patients 15 years after diagnosis.
Adjuvant tamoxifen does not provide an increase in
disease-free or overall survival in ER-negative breast
cancer. Five years of adjuvant tamoxifen alone is effective
in premenopausal women with ER. The benefits of
tamoxifen in lives saved from breast cancer far outweigh
concerns about an increased incidence of endometrial
cancer in postmenopausal women. Tamoxifen does not
increase the incidence of second cancers, endometrial
cancer excepted. No non-cancer-related overall survival
advantage was noted with tamoxifen when given as adju-
vant therapy. Therefore, in the management of breast
cancer, translational research with tamoxifen targeting
the ER with an appropriate duration (5 years) of adjuvant
therapy has demonstrated a contribution to the falling
national death rates from breast cancer. However, exten-
sive evaluation of tamoxifen treatment has revealed small
but significant side effects, such as endometrial cancer,
blood clots and the development of acquired resistance.
The solution was to develop drugs, and fortunately, an
exploration of the endocrine pharmacology of tamoxifen
and related nonsteroidal antiestrogens (e.g. raloxifene)
resulted in the laboratory recognition of selective ER
modulation and the translation of the concept to use
of raloxifene for the prevention of osteoporosis and
breast cancer. Tamoxifen and raloxifene are both SERMs,
which can block estrogen-mediated breast cancer growth
and development and also maintain bone mineral den-
sity in postmenopausal women, and lower circulating
cholesterol. The significant and continuing value of ralox-
ifene is that it has fulfilled its promise as an appropriate
medicine that targets specific populations for the pre-
vention of breast cancer [17,18]. The main differences
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seen between tamoxifen and raloxifene in relation to their
estrogenic and antiestrogenic properties relate to the
ability of the raloxifene side-chain to interact closely with
amino acid 351, thus further influencing the function
of the ER [16].
Raloxifene is now approved for use as prophylaxis to
diminish the risk of breast cancer in postmenopausal
women with osteoporosis and in postmenopausal wom-
en at high risk for invasive breast cancer. Clinical trial
data submitted to the Food and Drug Administration
(FDA) showed that the drug was effective as prophy-
laxis and that its effects were comparable to those of
tamoxifen, the only drug previously approved for the
prevention of breast cancer [19]. Like tamoxifen, ralox-
ifene posed a risk of serious adverse effects including
blood clots and stroke, but a lower risk of uterine malig-
nancies. Health care practitioners should note that the
expected benefits of raloxifene and the risks posed in
its use should be carefully evaluated for each patient,
and that the drug does not prevent breast cancer com-
pletely [19]. Of course, this limitation is also found in
the use of tamoxifen.
Based on the concept of using tamoxifen in the
“chemoprevention” of invasive breast cancer and the
long-term tolerance of many of the adverse events of
tamoxifen, raloxifene is a better alternative choice. Signifi-
cantly, the STAR trial clearly demonstrated the superiority
of raloxifene to tamoxifen not only in its equal efficacy
in the prevention of invasive breast cancer but also in a
lower incidence of serious adverse events, particularly
and most importantly, thromboembolism. However, in
patients with breast cancer, the superiority of raloxifene
to tamoxifen in terms of decreasing recurrence or pro-
longing disease-free survival has not been proved as yet.
Therefore, there should be caution in choosing raloxifene,
since neither the FDA nor clinical trials support this use.
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